Growth hormone axis
GHRP-2
Also called Pralmorelin, KP-102
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in Japan.
The human evidence for GHRP-2 used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.67mg/mL
- Volume per draw
- 0.06mL
- Units to dial
- 6
- Doses per cartridge
- 50
Vial label
Copy this into your label printer.
Published research contexts for GHRP-2 describe 100–100 mcg per administration. Descriptive only, not a recommendation.
Roughly 20–30 minutes; a short-acting secretagogue.
A growth-hormone secretagogue whose human evidence is a single 100 mcg intravenous dose given as a pituitary challenge, licensed in Japan. No subcutaneous dose-ranging schedule is established, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Pralmorelin (GHRP-2) growth-hormone challenge program, JapanLicensed as a single 100 mcg intravenous growth-hormone secretagogue challenge; the human data is the single-dose challenge, not a subcutaneous schedule.